Aegis Capital Restarts Opexa Therapeutics (OPXA) at Buy; Bullish on Secondary Progressive MS Progress
Tweet Send to a Friend
Aegis Capital is transferring coverage on Opexa Therapeutics (Nasdaq: OPXA), but maintains its Buy rating and places a price target ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
